Clinical Trial Update: PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update for PR104 in patients with refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia, sponsored by Proacta; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia

Drugs mentioned

• PR104

Snippet

Sponsor: Proacta, Incorporated | Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 1, Phase 2 | Status: UNKNOWN